Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

181. Cohort study: Influenza vaccination and egg allergy: another step forward

Cohort study: Influenza vaccination and egg allergy: another step forward Influenza vaccination and egg allergy: another step forward | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Influenza vaccination and egg allergy: another step forward Article Text Aetiology/Harm Cohort study Influenza vaccination and egg allergy: another step forward Anne Des Roches , Louis Paradis Statistics from Altmetric.com Commentary on: Turner PJ

2016 Evidence-Based Medicine

182. Pandemic flu

Pandemic flu Pandemic flu – Research from the 2009 outbreak Search this site or Dissemination Centre Pandemic Flu Every winter, many of us will get the flu. Most people will get better after a few days, but for certain vulnerable people, it can have serious consequences, including pneumonia. The prevailing strain of virus changes a little every year and an annual programme of immunisation, with a fresh vaccine, is conducted during the autumn in the UK. Some immunity carries over from year (...) to year for this ‘seasonal’ flu, but every few years a quite different flu virus emerges in the world causing a pandemic, to which most people do not have immunity. It can spread quickly because of the susceptibility of the population. Countries such as the UK have plans in place for pandemics, which include immunisation, treatment, separation of affected people, and health services to manage the potentially large numbers of people who suffer the effects and complications of flu. Lessons from the last

2016 NIHR Dissemination Centre - Highlights

183. WHO Global Action Plan for Influenza Vaccines report on online survey for the GAPIII consultation

WHO Global Action Plan for Influenza Vaccines report on online survey for the GAPIII consultation WHO Global Action Plan for Influenza Vaccines report on online survey for the GAPIII consultation JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links WHO Global Action Plan for Influenza Vaccines report on online survey for the GAPIII consultation View/ Open View Statistics Altmetrics (...) Share Citation World Health Organization . (‎2016)‎. WHO Global Action Plan for Influenza Vaccines report on online survey for the GAPIII consultation. World Health Organization. Description 39 p. Gov't Doc # WHO/HIS/TTi/GAP/16.1 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  World Health Organization (‎ 1998 )‎  World Health Assembly, 63 (‎ A63/48 , 2010 )‎  World Health Assembly, 64 (‎ A64/8A64/8 Corr.1 , 2011 )‎ View Item

2016 WHO

184. Barriers of influenza vaccination intention and behavior: a systematic review of influenza vaccine hesitancy 2005 – 2016

Barriers of influenza vaccination intention and behavior: a systematic review of influenza vaccine hesitancy 2005 – 2016 Barriers of influenza vaccination intention and behavior: a systematic review of influenza vaccine hesitancy 2005 – 2016 JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Barriers of influenza vaccination intention and behavior: a systematic review (...) of influenza vaccine hesitancy 2005 – 2016 View/ Open View Statistics Altmetrics Share Citation World Health Organization . (‎2016)‎. Barriers of influenza vaccination intention and behavior: a systematic review of influenza vaccine hesitancy 2005 – 2016. World Health Organization. Description 72 p. Gov't Doc # WHO/HIS/TTi/GAP/16.2 Collections Language English Metadata Related items Showing items related by title and MeSH subject.  World Health Assembly, 71 (‎ A71/24 , 2018 )‎  World Health Organization

2016 WHO

185. Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. Full Text available with Trip Pro

Safety of live attenuated influenza vaccine in young people with egg allergy: multicentre prospective cohort study. How safe is live attenuated influenza vaccine (LAIV), which contains egg protein, in young people with egg allergy?In this open label, phase IV intervention study, 779 young people (2-18 years) with egg allergy were recruited from 30 UK allergy centres and immunised with LAIV. The cohort included 270 (34.7%) young people with previous anaphylaxis to egg, of whom 157 (20.1%) had

2015 BMJ Controlled trial quality: predicted high

186. Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study

Tam JS, Williams TJ, Semple MG. Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study. Health Technology Assessment 2015; 19(89) Authors' objectives During pandemics of novel influenza and outbreaks of emerging infections, surge in health-care demand can exceed capacity to provide normal standards of care. In such exceptional circumstances, triage tools may aid decisions (...) Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge

2015 Health Technology Assessment (HTA) Database.

187. Nosocomial transmission of avian influenza A (H7N9) virus in China: epidemiological investigation. Full Text available with Trip Pro

Nosocomial transmission of avian influenza A (H7N9) virus in China: epidemiological investigation. Can avian influenza A (H7N9) virus be transmitted between unrelated individuals in a hospital setting?An epidemiological investigation looked at two patients who shared a hospital ward in February 2015, in Quzhou, Zhejiang Province, China. Samples from the patients, close contacts, and local environments were examined by real time reverse transcriptase (rRT) polymerase chain reaction (PCR (...) ) and viral culture. Haemagglutination inhibition and microneutralisation assays were used to detect specific antibodies to the viruses. Primary outcomes were clinical data, infection source tracing, phylogenetic tree analysis, and serological results.A 49 year old man (index patient) became ill seven days after visiting a live poultry market. A 57 year old man (second patient), with a history of chronic obstructive pulmonary disease, developed influenza-like symptoms after sharing the same hospital ward

2015 BMJ

188. Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design. Full Text available with Trip Pro

Maternal vaccination against H1N1 influenza and offspring mortality: population based cohort study and sibling design. What is the mortality in offspring of mothers who had influenza A(H1N1)pdm09 vaccination during pregnancy?This was a prospective population based cohort study in seven healthcare regions in Sweden based on vaccinations taking place between 2 October 2009 and 26 November 2010. H1N1 vaccination data were linked with pregnancy and birth characteristics and offspring mortality data (...) in 275,500 births (of which 1203 were stillbirths) from 137,886 mothers. Of these offspring, 41,183 had been exposed to vaccination with Pandemrix, a monovalent AS03 adjuvanted H1N1 influenza vaccine, during fetal life. A primary comparison group consisted of pregnancies of women who were not vaccinated during the same calendar period. In a second comparison, non-exposed siblings of infants prenatally exposed to vaccination were used as controls. Cox regression was used to estimate hazard ratios

2015 BMJ

189. Summary of the National Advisory Committee on Immunization (NACI) statement on seasonal influenza vaccine for 2015-2016

, as well as a revised definition for oculo-respiratory syndrome which, when it occurs, should be reported as an adverse event following immunization (AEFI) to local public health officials. Conclusion: Vaccination is the safest, longest lasting and most effective way to prevent influenza. Introduction Every year, the National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada with recommendations on seasonal influenza vaccines for the upcoming season as part of its (...) and are associated with an increased risk of aspiration morbid obesity (BMI ≥40) children and adolescents (aged 6 months to 18 years) with the following conditions: neurologic or neurodevelopment conditions (including seizure disorders, febrile seizures and isolated developmental delay) undergoing treatment for long periods with acetylsalicylic acid, because of the potential increase of Reye's syndrome associated with influenza. People of any age who are residents of nursing homes and other chronic care

2015 CPG Infobase

190. Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study Full Text available with Trip Pro

Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study Development of processes allowing near real-time refinement and validation of triage tools during the early stage of an outbreak in readiness for surge: the FLU-CATs Study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you

2015 NIHR HTA programme

191. Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination. Full Text available with Trip Pro

Association Between Hospitalization With Community-Acquired Laboratory-Confirmed Influenza Pneumonia and Prior Receipt of Influenza Vaccination. Few studies have evaluated the relationship between influenza vaccination and pneumonia, a serious complication of influenza infection.To assess the association between influenza vaccination status and hospitalization for community-acquired laboratory-confirmed influenza pneumonia.The Etiology of Pneumonia in the Community (EPIC) study (...) was a prospective observational multicenter study of hospitalizations for community-acquired pneumonia conducted from January 2010 through June 2012 at 4 US sites. In this case-control study, we used EPIC data from patients 6 months or older with laboratory-confirmed influenza infection and verified vaccination status during the influenza seasons and excluded patients with recent hospitalization, from chronic care residential facilities, and with severe immunosuppression. Logistic regression was used

2015 JAMA

192. Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study Full Text available with Trip Pro

Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study Early estimation of pandemic influenza Antiviral and Vaccine Effectiveness (EAVE): use of a unique community and laboratory national data-linked cohort study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found

2015 NIHR HTA programme

193. Fact Sheet: Non-pharmaceutical measures to prevent the transmission of influenza

Fact Sheet: Non-pharmaceutical measures to prevent the transmission of influenza NCCEH Fact Sheet: Non-pharmaceutical measures to prevent the transmission of in? uenza This fact sheet is for public health professionals. It provides a brief overview on speci? c non-pharmaceutical measures to be used in community settings. Such measures can prevent the spread of in? uenza by interrupting the transfer of viruses from objects or people through the use of personal protective equipment or changes

2015 National Collaborating Centre for Environmental Health

194. Human Infection with a Novel Avian Influenza A(H5N6) Virus. Full Text available with Trip Pro

Human Infection with a Novel Avian Influenza A(H5N6) Virus. 26222578 2015 08 14 2016 11 25 1533-4406 373 5 2015 Jul 30 The New England journal of medicine N. Engl. J. Med. Human Infection with a Novel Avian Influenza A(H5N6) Virus. 487-9 10.1056/NEJMc1502983 Yang Zi-Feng ZF State Key Laboratory of Respiratory Disease, Guangzhou, China. Mok Chris K P CK Peiris Joseph S M JS Zhong Nan-Shan NS eng Case Reports Letter Research Support, Non-U.S. Gov't United States N Engl J Med 0255562 0028-4793 AIM (...) IM Animals China Humans Influenza A virus classification isolation & purification Influenza in Birds Influenza, Human diagnosis therapy virology Lung diagnostic imaging pathology Male Middle Aged Poultry Radiography 2015 7 30 6 0 2015 7 30 6 0 2015 8 15 6 0 ppublish 26222578 10.1056/NEJMc1502983

2015 NEJM

195. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. Human infections with the avian influenza A(H7N9) virus were first reported in China in 2013 and continue to occur. Hemagglutinin H7 administered alone is a poor immunogen necessitating evaluation of adjuvanted H7N9 vaccines.To evaluate the immunogenicity and safety of an inactivated H7N9 vaccine with and without AS03 adjuvant, as well as mixed (...)  = 96) (103.4 [95% CI, 78.7-135.9]; P < .001) but higher GMTs than 2 doses of MF59-adjuvanted formulation (n = 94) (29.0 [95% CI, 22.4-37.6]; P < .001).The AS03 and MF59 adjuvants augmented the immune responses to 2 doses of an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest titers. This study of 2 adjuvants used in influenza vaccine formulations with adjuvant mixed on site provides immunogenicity information that may be informative to influenza pandemic

2015 JAMA Controlled trial quality: predicted high

196. Population-level susceptibility, severity and spread of pandemic influenza: design of, and initial results from, a pre-pandemic and hibernating pandemic phase study using cross-sectional data from the Health Survey for England (HSE) Full Text available with Trip Pro

Population-level susceptibility, severity and spread of pandemic influenza: design of, and initial results from, a pre-pandemic and hibernating pandemic phase study using cross-sectional data from the Health Survey for England (HSE) Population-level susceptibility, severity and spread of pandemic influenza: design of, and initial results from, a pre-pandemic and hibernating pandemic phase study using cross-sectional data from the Health Survey for England (HSE) Journals Library An error has

2015 NIHR HTA programme

197. Interventions effective in increasing influenza vaccination rates

Interventions effective in increasing influenza vaccination rates Interventions effective in increasing influenza vaccination rates | Cochrane Primary Care Trusted evidence. Informed decisions. Better health. Enter terms Interventions effective in increasing influenza vaccination rates Cochrane Trusted evidence. Informed decisions. Better health. Copyright © 2019 The Cochrane Collaboration | | We use cookies to improve your experience on our site.

2015 Cochrane PEARLS

198. Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial in hibernation, ready for rapid activation

Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial in hibernation, ready for rapid activation Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial in hibernation, ready for rapid activation Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial (...) . Blinded randomised controlled trial of low-dose Adjuvant Steroids in Adults admitted to hospital with Pandemic influenza (ASAP): a trial in hibernation, ready for rapid activation. Health Technology Assessment 2015; 19(16) Authors' objectives To (1) evaluate whether or not low-dose corticosteroids given as an adjunct to standard treatment is beneficial in patients who are hospitalised with severe pandemic influenza and (2) develop an 'off-the-shelf' clinical trial that is ready to be activated

2015 Health Technology Assessment (HTA) Database.

199. Planning for a cohort study to investigate the impact and management of influenza in pregnancy in a future pandemic Full Text available with Trip Pro

Planning for a cohort study to investigate the impact and management of influenza in pregnancy in a future pandemic Planning for a cohort study to investigate the impact and management of influenza in pregnancy in a future pandemic Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find

2015 NIHR HTA programme

200. Fluenz Tetra - seasonal influenza in children

Fluenz Tetra - seasonal influenza in children FLUENZTETRA SUMMARY CT13920

2015 Haute Autorite de sante